Clinical trial
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved…
NCT00473889 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00473889 |
|---|---|
| Title | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) |
| Official title | A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Stage IIIB or IV Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | vorinostat, Comparator: paclitaxel, Comparator: carboplatin, Comparator: placebo |
| Enrollment | 253 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 16, 2007 |
| Last update posted | Jul 3, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: